Business Wire

LR Health & Beauty: From 5-man Business to Successful Global Player

13.7.2020 12:48:00 CEST | Business Wire | Press Release

Share

Celebrities who develop their own fragrances, black cars featuring the company logo and collaboration with well-known institutions such as Dermatest GmbH – this is what we associate with LR Health & Beauty nowadays. But back in 1985, the year LR was founded, things were still quite different. At the tender age of 25, miner Helmut Spikker, who left the company in 2005, founded “L’arôme Parfümerie- und Kosmetikartikel GmbH”. At first it was just a 5-man company that offered nothing but a number of perfumes and personal care products. On 17 September 1985, the company was renamed “LR Cosmetic”.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200713005294/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

For 35 years, LR Health & Beauty has been setting new standards with beauty and wellness products. It is one of Europe’s leading direct marketing enterprises, which means that all sales are conducted via independent sales partners. (Photo: Business Wire)

“This name would no longer be suitable these days, because our product portfolio has grown so much: In addition to perfumes and indulgent and beautiful cosmetics, our focus now lies on nutritional supplements, which make up around 60 % of our worldwide sales. ‘LR Health & Beauty’ is a more apt name,” explains Andreas Friesch, CEO and LR spokesperson. A lot has happened over the years, also with regard to the workforce. The company currently has around 1,200 employees, of whom roughly 700 are employed in Ahlen.

Based in Ahlen, at home in the world

The Westphalian mining town continues to play a crucial role for LR. For LR, Ahlen not only means home – Ahlen is also where the headquarters and control hub of the company are and where all the important decisions are made. Nevertheless, the company is now also at home across the world: in addition to the German market, LR currently sells its products in 27 other European countries. “Most of our sales partners, especially our long-term partners, have a very special relationship with LR. I am very glad about that. But we also want to interest new people in the LR business. Which means we need to take a close look at other markets,” says Friesch.

Quirky products and well-known celebrities as part of LR history

LR has reached many milestones in its 35-year history. These include the moment we started offering nutritional supplements (2000) and our best-selling Aloe Vera Drinking Gel (2002), the completion of our new company headquarters on Kruppstrasse in Ahlen after 20 months of construction (2002), the entry in the Guinness Book of Records (for creating the LR logo with 265 VW Polos; 2008), the foundation of the children’s charity LR Global Kids Fund (2009), receiving the award for best European direct sales company of the year (2015), the opening of our state-of-the-art aloe vera production plant (2018) and receiving the Ahlen economic award “Wirtschaftspreis der Stadt Ahlen” (2019).

In the fragrance segment, the company continues to work with top celebrities. With more than 30 names, the list of stars is already very long and keeps on growing. LR is currently collaborating with Guido Maria Kretschmer, Bruce Willis, Emma Heming-Willis and the Portuguese TV presenter Cristina Ferreira. “Whenever the stars appear at our events, it creates a total buzz among our sales partners," reveals Heursen.

Company continues to look ahead

Despite the many developments, one thing remains the same, even after 35 years: LR has been relying on direct marketing since 1985, which means that the products are sold directly through independent sales partners, who can in turn recruit, train and organise new sales partners. “The question we constantly ask ourselves is ‘How can we best support our partners with their business activities?’,” stresses Friesch. Without wanting to reveal too much, he offers a glimpse at the future: “We will continue to focus on innovative products. Since we are at home in direct marketing and manufacture many of our products ourselves, we are always keen to hear from our sales partners. They tell us what their customers want, which allows us to react particularly quickly to market needs – this proximity to customers and flexibility distinguishes us from many other competitors.”

LR Health & Beauty

Under the motto “More quality for your life“, the LR Group with headquarters in Ahlen/Westphalia produces and markets various health and beauty products in around 28 countries. The range includes care and decorative cosmetics, dietary supplements and perfumes. With its portfolio, LR Health & Beauty aims to enhance the physical health and wellbeing of people. That is why the company continuously develops new products – from the power of nature in combination with the latest scientific findings. The processing of Aloe vera has been one of the core competencies of LR Health & Beauty for more than 17 years. Only the valuable inside of the leaf is used for the products. In Ahlen, the company has established the most modern Aloe Vera production site for Aloe Vera Drinking Gels in Europe. In the fragrance segment, LR cooperates with national and international stars such as Guido Maria Kretschmer, Bruce Willis, Emma Heming-Willis and Cristina Ferreira. With 1,200 employees as well as thousands of registered sales partners and customers, LR is one of Europe’s leading direct sales enterprises. LR also established the LR Global Kids Fund e.V. which provides efficient and unbureaucratic support for deprived children and their families in many different countries around the world in cooperation with local institutions.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

LR Health & Beauty
Almut Kellermeyer
Head of PR / Public Affairs
Tel: +49 2382 7060-106
Email: A.Kellermeyer@LRworld.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye